Navigation Links
Advanced Cell Technology Announces 2011 First Quarter Results
Date:5/9/2011

MARLBOROUGH, Mass., May 9, 2011 /PRNewswire/ -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today first quarter financial results for the period ended March 31, 2011. The Company reported a loss from operations of $(4.8) million compared to a loss from operations of $(15.0) million in the 2010 first quarter.  ACT reported a net loss of $(3.3) million or $(0.00) per share, compared to a loss in the same period in 2010 of $(17.8) million, or $(0.03) per share.

Net cash used in operations for the 2011 first quarter was $3.4 million, compared to net cash used in operations of $2.9 million in the same period in 2010. The Company ended the 2011 first quarter with cash and cash equivalents of $13.7 million, compared to $15.9 million as of December 31, 2010.

"During the first quarter of this year, ACT made significant progress in securing sites to conduct our Phase 1/2 clinical trials for Stargardt's Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (Dry AMD), as reflected by our recent announcement that the Jules Stein Eye Institute at the University of California, Los Angeles (UCLA) has received institutional review board (IRB) approval to be a site for both the SMD and AMD trials using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs)," said Gary Rabin, interim Chairman and CEO of ACT.  "We also recently filed a clinical trial application with the European Medicines and Healthcare products Regulatory Agency (MHRA) seeking clearance to initiate a similar SMD trial in Europe. We believe that these trials represent excellent opportunities to evaluate the potential for RPE cells to repair and regenerate the retina."

"While we are excited about the scientific potential for our RPE platform, we also believe that our strong balance sheet and access to capital positions us well to negotiate strategic partnerships or licensing agreements," continued Mr. Rabin. "With the Company's existing cash on hand as well as access to capital, ACT has the financial strength to complete the Phase 1/2 trials, which could represent important value-creation opportunities for the Company."

The Company plans to conduct a webcast of the informal portion of its Annual Shareholder's Meeting in June. Additional details will be provided as the event approaches.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-K for the year ended December 31, 2010.  Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company's clinical trials will be successful.

Contact:

Investors:
CEOcast, Inc., James Young, 212-732-4300

Press:
ACT Corporate Communications, Bill Douglass, 646-450-3615
or:
Russo Partners, Martina Schwarzkopf, Ph.D., 212-845-4292


'/>"/>
SOURCE Advanced Cell Technology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Advanced Life Sciences Awarded U.S. Department of Defense Biodefense Contract Valued at up to $3.8 Million
2. Advanced Life Sciences Announces Second Quarter 2008 Financial Results
3. LUMEDX Introduces Advanced Multi-Modality, Multi-Vendor, Web-Enabled ECG Management Solution
4. Waters Brings Advanced Laboratory Data Management to Microsofts BioIT Alliance
5. Orange Coast Urology Offers Advanced In-Office Patient EVOLVE(R) Laser Prostate Treatment
6. Advanced Pest Control Earns Quality Pro Designation for General Pest Control Services
7. Independent Monitoring Board Recommends Completion of Accrual to Genasense(R) Phase 3 AGENDA Trial in Advanced Melanoma
8. Advanced Chemical Transport Opens Merced Facility
9. Advanced Life Sciences to Host Conference Call to Update Investors on Progress of Corporate Initiatives on October 1, 2008
10. Advanced Instruments Acquires D & F Control Systems Inc.
11. DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... PHOENIX and SAN DIEGO ... (OTCQB:CELZ) announced the appointment of Santosh Kesari , ... Board. Dr. Kesari will leverage his experience in neurology and ... its adult stem cell for treatment of stroke. The AmnioStem ... amniotic fluid, which has previously shown therapeutic activity in ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... on discovery and development of precision treatments for neurodegenerative diseases, today announced ... disease (AD) inhibited the direct neurotoxic effect of prion-like forms of Amyloid ...
(Date:12/5/2016)... DUBLIN , Dec 5, 2016 ... report "Biomarkers - Technologies, Markets and Companies" to their ... , , ... biomarkers and their discovery using various -omics technologies such as proteomics ... biomarkers and new tests are also based on biomarker. ...
(Date:12/5/2016)... SAN DIEGO , Dec. 5, 2016 /PRNewswire-USNewswire/ ... treatments for congestive heart failure and other chronic ... is joining the company as Chief Financial Officer ... Renova Therapeutics with 20 years of experience in ... closely held biotech and software companies. Most recently, ...
Breaking Biology Technology:
(Date:12/6/2016)... N.C. , Dec. 6, 2016 Valencell ... announced today it has seen a third consecutive year ... biometric sensor technology in 2016 with a 360 percent ... last year. This increase was driven by sales of ... as robust interest in its technology for hearables for ...
(Date:12/2/2016)... , December 1, 2016 ... type (Fingerprint, Voice), Future Technology (Iris Recognition System), ... Region - Global Forecast to 2021", published by ... 442.7 Million in 2016, and is projected to ... a CAGR of 14.06%.      (Logo: ...
(Date:11/30/2016)... CHICAGO , Nov. 30, 2016  higi ... a new partnership initiative targeting national brands, industry ... and reward their respective audiences for taking steps ... Since its inception in 2012, higi has built ... US, impacting over 38 million people who have ...
Breaking Biology News(10 mins):